

Dear Customer,

Sustainability, continuity and stability are very important characteristics for Rottendorf Pharma within its market environment. Characteristics that may also have influenced the customers' decision to work with Rottendorf Pharma.

In order to strengthen these characteristics the board of directors around Dr. Stephan Fleck has decided that from June 1st, 2018 onwards Rottendorf Pharma will be led by two executive officers ensuring continued leadership even in case of loss of one person.

The board of directors is pleased to announce that Dr. Silke Huster has been appointed as second Executive Officer next to Dr. Stephan Fleck.

Dr. Silke Huster has been with Rottendorf Pharma since 2007 and has broad experience within the pharmaceutical industry. In her latest function as Senior Director Product Supply she held the overall responsibility for commercial operations at Rottendorf Pharma. She will continue leading this function while her area of responsibilities will increase.

Dr. Stephan Fleck will continue leading the strategic and business oriented functions of Rottendorf Pharma, which are Technology, Business and Strategy.

With this organizational change Rottendorf Pharma is strengthening its focus on stability and continuity for the benefit of all Rottendorf Pharma customers ensuring long term sustainability.

Yours faithfully
Dr. Stephan Fleck

